Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study

医学 心脏病学 内科学 肥厚性心肌病 射血分数 安慰剂 梗阻性肥厚性心肌病 心肌病 临床试验 心室流出道 心力衰竭 不利影响 梗阻性心肌病 临床疗效 心率 物理疗法 随机对照试验 探索性分析 年轻人
作者
Zhuang Tian,Xiaoyan Li,Li Li,Qing Zhang,Jianan Wang,Y Q Shi,D Q Peng,Wei Ma,Ping Yang,Xiang Cheng,Wei Jin,Fang Wang,Yimeng Xie,Beth Pan,Victoria Florea,Shuyang Zhang
出处
期刊:Journal of the American Heart Association [Wiley]
卷期号:15 (11): e046251-e046251
标识
DOI:10.1161/jaha.125.046251
摘要

BACKGROUND: Long-term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown. METHODS: Patients who completed the 30-week, double-blind, placebo-controlled treatment period in EXPLORER-CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM), with no active safety concerns, were eligible to enter the long-term extension period to receive 48-week mavacamten treatment. Patients previously on mavacamten continued mavacamten (dose at week 30; mavacamten-mavacamten group); patients previously on placebo received mavacamten (starting dose, 2.5 mg once daily; placebo-mavacamten group). Key efficacy end points included change from baseline in echocardiographic measures, New York Heart Association functional class, 23-item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. Analyses were descriptive; no between-group hypothesis testing was performed. RESULTS: Seventy-nine patients (mean age, 51.6 years; 27.8% women) entered the long-term extension period (mavacamten-mavacamten, n=54; placebo-mavacamten, n=25). In the mavacamten-mavacamten group, numerical improvements in Valsalva and resting left ventricular outflow tract peak gradients were maintained through week 78 (mean change from baseline, -73.0 mm Hg [95% CI, -86.4 to -59.5]; and -56.3 mm Hg [95% CI, -67.1 to -45.5], respectively). Numerical improvements were also observed for other echocardiographic parameters, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. In the placebo-mavacamten group, numerical improvements with mavacamten in these parameters were noted from week 30 to week 78. Long-term mavacamten treatment appeared well tolerated; left ventricular ejection fraction <50% was rare. CONCLUSIONS: In this exploratory long-term extension study, 78-week mavacamten treatment appeared well-tolerated and was associated with numerical improvements from baseline in echocardiographic parameters, New York Heart Association class, patient-reported health status, and cardiac biomarkers in Chinese patients with obstructive hypertrophic cardiomyopathy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05174416.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火山发布了新的文献求助10
刚刚
飘逸小天鹅完成签到,获得积分20
刚刚
tzhang16发布了新的文献求助10
1秒前
1秒前
丘比特的应助被甜甜采纳,获得10
1秒前
喜悦的威完成签到,获得积分10
1秒前
上官若男的应助被善良语雪采纳,获得10
2秒前
无极微光的应助被科研新牛马采纳,获得20
3秒前
小猪发布了新的文献求助10
3秒前
完美世界的应助被过过过采纳,获得20
3秒前
3秒前
4秒前
4秒前
852的应助被liko采纳,获得10
4秒前
hyshen完成签到,获得积分10
5秒前
5秒前
科研通AI6.2的应助被匆匆采纳,获得10
6秒前
Transparent完成签到,获得积分10
6秒前
7秒前
ge_jn完成签到,获得积分20
7秒前
默z发布了新的文献求助10
7秒前
bob完成签到,获得积分10
7秒前
小木完成签到,获得积分10
8秒前
8秒前
9秒前
赫江涛发布了新的文献求助10
9秒前
张天发布了新的文献求助10
10秒前
Kai完成签到,获得积分10
11秒前
超级飞侠完成签到,获得积分10
12秒前
12秒前
范海辛完成签到,获得积分10
12秒前
甜甜发布了新的文献求助10
13秒前
14秒前
14秒前
善良语雪发布了新的文献求助10
15秒前
哈温温完成签到,获得积分10
15秒前
aaa完成签到 ,获得积分10
15秒前
16秒前
江子川发布了新的文献求助10
16秒前
无极微光的应助被阳光的山水采纳,获得20
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698